These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. Czuczman MS; Weaver R; Alkuzweny B; Berlfein J; Grillo-López AJ J Clin Oncol; 2004 Dec; 22(23):4711-6. PubMed ID: 15483015 [TBL] [Abstract][Full Text] [Related]
3. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network. Hainsworth JD; Litchy S; Shaffer DW; Lackey VL; Grimaldi M; Greco FA J Clin Oncol; 2005 Feb; 23(6):1088-95. PubMed ID: 15657401 [TBL] [Abstract][Full Text] [Related]
4. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network. Hainsworth JD; Litchy S; Morrissey LH; Andrews MB; Grimaldi M; McCarty M; Greco FA J Clin Oncol; 2005 Mar; 23(7):1500-6. PubMed ID: 15632411 [TBL] [Abstract][Full Text] [Related]
5. The therapeutic use of rituximab in non-Hodgkin's lymphoma. Marcus R; Hagenbeek A Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982 [TBL] [Abstract][Full Text] [Related]
6. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma]. Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686 [TBL] [Abstract][Full Text] [Related]
7. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma]. Zhang HY; Lin TY; Jiang WQ; Zhang L; Huang HQ; Xia ZJ; Sun XF; He YJ; Guan ZZ Ai Zheng; 2004 Dec; 23(12):1681-6. PubMed ID: 15601560 [TBL] [Abstract][Full Text] [Related]
8. The role of mitoxantrone in the treatment of indolent lymphomas. Hagemeister F; Cabanillas F; Coleman M; Gregory SA; Zinzani PL Oncologist; 2005 Feb; 10(2):150-9. PubMed ID: 15709217 [TBL] [Abstract][Full Text] [Related]
9. Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. Czuczman MS; Koryzna A; Mohr A; Stewart C; Donohue K; Blumenson L; Bernstein ZP; McCarthy P; Alam A; Hernandez-Ilizaliturri F; Skipper M; Brown K; Chanan-Khan A; Klippenstein D; Loud P; Rock MK; Benyunes M; Grillo-Lopez A; Bernstein SH J Clin Oncol; 2005 Feb; 23(4):694-704. PubMed ID: 15681517 [TBL] [Abstract][Full Text] [Related]
10. One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2/IgH positive cells: Is the end of molecular monitoring near? Schmitt C; Grundt A; Buchholtz C; Scheuer L; Benner A; Hensel M; Ho AD; Leo E Leuk Res; 2006 Dec; 30(12):1563-8. PubMed ID: 16530831 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of rituximab plus chemotherapy in follicular lymphoma depends on Ki-67 expression. Saito B; Shiozawa E; Yamochi-Onizuka T; Adachi D; Nakamaki T; Tomoyasu S; Omine M; Mitsuya T; Takimoto M; Ota H Pathol Int; 2004 Sep; 54(9):667-74. PubMed ID: 15363034 [TBL] [Abstract][Full Text] [Related]
12. [Rituximab]. Okamoto R; Maeda Y; Sasaki T Gan To Kagaku Ryoho; 2003 Aug; 30(8):1085-93. PubMed ID: 12938262 [TBL] [Abstract][Full Text] [Related]
13. Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study. Sebban C; Brice P; Delarue R; Haioun C; Souleau B; Mounier N; Brousse N; Feugier P; Tilly H; Solal-Céligny P; Coiffier B J Clin Oncol; 2008 Jul; 26(21):3614-20. PubMed ID: 18559872 [TBL] [Abstract][Full Text] [Related]
14. Rituximab in autologous stem cell transplantation for follicular lymphoma. Schmitz N Anticancer Drugs; 2001 Jun; 12 Suppl 2():S21-4. PubMed ID: 11508933 [TBL] [Abstract][Full Text] [Related]
15. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. Witzig TE; Vukov AM; Habermann TM; Geyer S; Kurtin PJ; Friedenberg WR; White WL; Chalchal HI; Flynn PJ; Fitch TR; Welker DA J Clin Oncol; 2005 Feb; 23(6):1103-8. PubMed ID: 15657404 [TBL] [Abstract][Full Text] [Related]
16. Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. Strauss SJ; Morschhauser F; Rech J; Repp R; Solal-Celigny P; Zinzani PL; Engert A; Coiffier B; Hoelzer DF; Wegener WA; Teoh NK; Goldenberg DM; Lister TA J Clin Oncol; 2006 Aug; 24(24):3880-6. PubMed ID: 16864854 [TBL] [Abstract][Full Text] [Related]